These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

350 related items for PubMed ID: 16163699

  • 1. Signal transduction of erbB receptors in trastuzumab (Herceptin) sensitive and resistant cell lines: local stimulation using magnetic microspheres as assessed by quantitative digital microscopy.
    Friedländer E, Arndt-Jovin DJ, Nagy P, Jovin TM, Szöllosi J, Vereb G.
    Cytometry A; 2005 Oct; 67(2):161-71. PubMed ID: 16163699
    [Abstract] [Full Text] [Related]

  • 2. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.
    Zsebik B, Citri A, Isola J, Yarden Y, Szöllosi J, Vereb G.
    Immunol Lett; 2006 Apr 15; 104(1-2):146-55. PubMed ID: 16384610
    [Abstract] [Full Text] [Related]

  • 3. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
    Diermeier S, Horváth G, Knuechel-Clarke R, Hofstaedter F, Szöllosi J, Brockhoff G.
    Exp Cell Res; 2005 Apr 01; 304(2):604-19. PubMed ID: 15748904
    [Abstract] [Full Text] [Related]

  • 4. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line.
    Nagy P, Friedländer E, Tanner M, Kapanen AI, Carraway KL, Isola J, Jovin TM.
    Cancer Res; 2005 Jan 15; 65(2):473-82. PubMed ID: 15695389
    [Abstract] [Full Text] [Related]

  • 5. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
    Motoyama AB, Hynes NE, Lane HA.
    Cancer Res; 2002 Jun 01; 62(11):3151-8. PubMed ID: 12036928
    [Abstract] [Full Text] [Related]

  • 6. Concurrent biological targeting therapy of squamous cell carcinoma of the esophagus with cetuximab and trastuzumab.
    Yamazaki M, Yamashita Y, Kubo N, Yashiro M, Ohira M, Ako E, Tanaka H, Muguruma K, Sawada T, Hirakawa K.
    Oncol Rep; 2012 Jul 01; 28(1):49-54. PubMed ID: 22562413
    [Abstract] [Full Text] [Related]

  • 7. PC cell-derived growth factor stimulates proliferation and confers Trastuzumab resistance to Her-2-overexpressing breast cancer cells.
    Kim WE, Serrero G.
    Clin Cancer Res; 2006 Jul 15; 12(14 Pt 1):4192-9. PubMed ID: 16857791
    [Abstract] [Full Text] [Related]

  • 8. The ErbB/HER family of protein-tyrosine kinases and cancer.
    Roskoski R.
    Pharmacol Res; 2014 Jan 15; 79():34-74. PubMed ID: 24269963
    [Abstract] [Full Text] [Related]

  • 9. Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin.
    Yuste L, Montero JC, Esparís-Ogando A, Pandiella A.
    Cancer Res; 2005 Aug 01; 65(15):6801-10. PubMed ID: 16061662
    [Abstract] [Full Text] [Related]

  • 10. EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance.
    Dua R, Zhang J, Nhonthachit P, Penuel E, Petropoulos C, Parry G.
    Breast Cancer Res Treat; 2010 Aug 01; 122(3):685-97. PubMed ID: 19859802
    [Abstract] [Full Text] [Related]

  • 11. Cetuximab enhances the anti-proliferative effect of trastuzumab in ERBB2 over-expressing breast cancer cells--preliminary study.
    Uberall I, Krízová K, Steigerová J.
    Klin Onkol; 2011 Aug 01; 24(5):356-60. PubMed ID: 22070017
    [Abstract] [Full Text] [Related]

  • 12. Controlled activation of ErbB1/ErbB2 heterodimers promote invasion of three-dimensional organized epithelia in an ErbB1-dependent manner: implications for progression of ErbB2-overexpressing tumors.
    Zhan L, Xiang B, Muthuswamy SK.
    Cancer Res; 2006 May 15; 66(10):5201-8. PubMed ID: 16707444
    [Abstract] [Full Text] [Related]

  • 13. Associations of ErbB2, beta1-integrin and lipid rafts on Herceptin (Trastuzumab) resistant and sensitive tumor cell lines.
    Mocanu MM, Fazekas Z, Petrás M, Nagy P, Sebestyén Z, Isola J, Tímár J, Park JW, Vereb G, Szöllosi J.
    Cancer Lett; 2005 Sep 28; 227(2):201-12. PubMed ID: 16112423
    [Abstract] [Full Text] [Related]

  • 14. ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines.
    Ginestier C, Adélaïde J, Gonçalvès A, Repellini L, Sircoulomb F, Letessier A, Finetti P, Geneix J, Charafe-Jauffret E, Bertucci F, Jacquemier J, Viens P, Birnbaum D.
    Oncogene; 2007 Nov 01; 26(50):7163-9. PubMed ID: 17525746
    [Abstract] [Full Text] [Related]

  • 15. Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression.
    Menendez JA, Mehmi I, Lupu R.
    J Clin Oncol; 2006 Aug 10; 24(23):3735-46. PubMed ID: 16847284
    [Abstract] [Full Text] [Related]

  • 16. Epidermal growth factor and betacellulin mediate signal transduction through co-expressed ErbB2 and ErbB3 receptors.
    Alimandi M, Wang LM, Bottaro D, Lee CC, Kuo A, Frankel M, Fedi P, Tang C, Lippman M, Pierce JH.
    EMBO J; 1997 Sep 15; 16(18):5608-17. PubMed ID: 9312020
    [Abstract] [Full Text] [Related]

  • 17. The relative role of ErbB1-4 receptor tyrosine kinases in radiation signal transduction responses of human carcinoma cells.
    Bowers G, Reardon D, Hewitt T, Dent P, Mikkelsen RB, Valerie K, Lammering G, Amir C, Schmidt-Ullrich RK.
    Oncogene; 2001 Mar 15; 20(11):1388-97. PubMed ID: 11313882
    [Abstract] [Full Text] [Related]

  • 18. Transactivation of ErbB1 and ErbB2 receptors by angiotensin II in normal human prostate stromal cells.
    Lin J, Freeman MR.
    Prostate; 2003 Jan 01; 54(1):1-7. PubMed ID: 12481249
    [Abstract] [Full Text] [Related]

  • 19. Growth stimulation of non-small cell lung cancer cell lines by antibody against epidermal growth factor receptor promoting formation of ErbB2/ErbB3 heterodimers.
    Maegawa M, Takeuchi K, Funakoshi E, Kawasaki K, Nishio K, Shimizu N, Ito F.
    Mol Cancer Res; 2007 Apr 01; 5(4):393-401. PubMed ID: 17426253
    [Abstract] [Full Text] [Related]

  • 20. In vivo activity of novel anti-ErbB2 antibody chA21 alone and with Paclitaxel or Trastuzumab in breast and ovarian cancer xenograft models.
    Shen G, Huang H, Zhang A, Zhao T, Hu S, Cheng L, Liu J, Xiao W, Ling B, Wu Q, Song L, Wei W.
    Cancer Immunol Immunother; 2011 Mar 01; 60(3):339-48. PubMed ID: 21086124
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.